Ad
related to: new drug to stop pah posttemu.com has been visited by 1M+ users in the past month
- Women's Clothing
Limited time offer
Hot selling items
- Today's hottest deals
Up To 90% Off For Everything
Countless Choices For Low Prices
- Top Sale Items
Daily must-haves
Special for you
- Sale Zone
Special for you
Daily must-haves
- Women's Clothing
Search results
Results from the WOW.Com Content Network
Selexipag, sold under the brand name Uptravi, is a medication developed by Actelion for the treatment of pulmonary arterial hypertension (PAH). [3] [4] Selexipag and its active metabolite, ACT-333679 (or MRE-269, the free carboxylic acid), are agonists of the prostacyclin receptor, which leads to vasodilation in the pulmonary circulation. [5]
Iloprost, sold under the brand name Ventavis among others, is a medication used to treat pulmonary arterial hypertension (PAH), scleroderma, Raynaud's phenomenon, frostbite, and other conditions in which the blood vessels are constricted and blood cannot flow to the tissues. [4] Iloprost is a prostacyclin mimetic. [1]
Sitaxentan is a small molecule that blocks the action of endothelin (ET) on the endothelin-A (ET A) receptor selectively (by a factor of 6000 compared with the ET B). [3] It is a sulfonamide class endothelin receptor antagonist (ERA) and is undergoing Food and Drug Administration (FDA) review for treating pulmonary hypertension.
For premium support please call: 800-290-4726 more ways to reach us
Arena (ARNA) inks a deal to out-license global rights to its phase III candidate, ralinepag, to United Therapeutics. Shares of the company rally 22% following this news.
The Chronic Thromboembolic Pulmonary Hypertension sGC-Stimulator Trial (CHEST) was a randomized, placebo-controlled trial aimed to analyse the efficacy and safety of riociguat in CTEPH patients. [20] After a 16-week riociguat treatment the patient's exercise capacity were evaluated by measuring the change in the six-minute walk test (6-MWT). [21]
Pulmonary arterial hypertension (PAH) is a serious condition that happens when the tiny vessels in your lungs narrow, resulting in high blood pressure. Normally, the pulmonary artery supplies ...
Macitentan, sold under the brand name Opsumit, is an endothelin receptor antagonist developed by Actelion and approved for the treatment of pulmonary arterial hypertension (PAH). [5] Macitentan is a dual endothelin receptor antagonist, meaning that it acts as an antagonist of two endothelin (ET) receptor subtypes, ET A and ET B . [ 5 ]
Ad
related to: new drug to stop pah posttemu.com has been visited by 1M+ users in the past month